Abstract | BACKGROUND:
Ferumoxytol is a safe and effective parenteral therapy used for the treatment of iron deficiency anaemia that has recently been approved for use in North America and in Europe. METHODS:
Ferumoxytol consists of a superparamagnetic iron oxide ( SPIO) core, which causes T1, T2 and T2* shortening effects, and a carbohydrate shell, which results in a prolonged intravascular half life. RESULTS: These properties are under-reported and not well recognised. They can interfere with MRI interpretation, potentially masking enhancement and rendering examinations non-diagnostic or simulating pathologic disease states. Both radiologists and non-radiologist physicians must consider the potential interaction of ferumoxytol with MRI when interpreting and prescribing MRI examinations in their patients. MAIN MESSAGES:
|
Authors | Nicola Schieda |
Journal | Insights into imaging
(Insights Imaging)
Vol. 4
Issue 4
Pg. 509-12
(Aug 2013)
ISSN: 1869-4101 [Print] Germany |
PMID | 23756996
(Publication Type: Journal Article)
|